Mesoblast Limited has drawn US$50 million from a five-year non-dilutive facility provided by shareholder and director Dr. Gregory George, using the proceeds to retire higher-cost debt and optimize its capital structure. The move signals confidence in the company’s commercial prospects while materially improving its financial flexibility and eliminating near-term refinancing pressure.
The facility carries a fixed interest rate of 8.00 percent per annum, representing a substantial reduction from Mesoblast’s prior debt facilities. The structure offers a five-year interest-only period from the initial draw, with repayment available at any time without early prepayment fees or other exit charges. These terms stand in marked contrast to the NovaQuest Capital Management LLC debt facility being retired, which carried higher rates and shorter maturities that created pressure to refinance in unfavorable market conditions. Securing the facility solely against the Temcell royalty stream is also strategically valuable, as it leaves the company’s material assets and extensive intellectual property portfolio unencumbered for use in potential partnerships or licensing transactions.
As of March 30, 2026, Mesoblast held US$122 million in cash. Combined with the US$50 million drawn under the new facility, the company now possesses approximately US$172 million in liquid resources, assuming normal operating cash burn. This capital base comfortably funds the company’s commercial operations, which include commercializing Ryoncil, its FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients, and advancing its development pipeline. The strengthened balance sheet also preserves optionality for strategic partnerships and licensing arrangements, areas where unencumbered assets and clear intellectual property ownership are significant negotiating advantages.
The non-dilutive nature of the facility carries particular importance for existing shareholders. Unlike equity raises or warrant offerings, this financing structure does not create new shares and therefore does not dilute ownership stakes. The participation of Dr. Gregory George, both a major shareholder and board member, underscores alignment between company leadership and significant shareholders regarding strategic priorities and capital allocation.
From an investor perspective, the announcement demonstrates prudent financial management at a critical juncture. Mesoblast is transitioning toward a commercial-stage business with an FDA-approved product and multiple pipeline candidates in development. The elimination of short-term debt maturities removes refinancing risk during this transition period, while the improved borrowing terms reflect the company’s strengthened negotiating position with creditors and investors.
Investors should focus on Mesoblast’s commercial execution with Ryoncil, including prescription uptake trends and reimbursement progress, alongside development progress in additional indications such as adult steroid-refractory acute graft-versus-host disease and biologic-resistant inflammatory bowel disease. Cash burn rates relative to the company’s expanded liquidity position warrant monitoring. This announcement is price sensitive and has been flagged as material by the Australian Securities Exchange.
View the full ASX announcement (PDF)
About Mesoblast Limited (ASX: MSB)
Mesoblast Limited is a biotechnology company headquartered in Melbourne, Australia, specializing in the development of allogeneic cellular medicines derived from adult stem cells. The company focuses on treating severe and life-threatening inflammatory conditions, with a pipeline spanning cardiovascular diseases, spine orthopedic disorders, and immune-mediated conditions. It is a world leader in the development of off-the-shelf cellular medicine therapies for these therapeutic areas.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
